Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences’ oncology pipeline is exciting—but its SEC paperwork can feel like a clinical protocol. Each annual report dissects Phase 3 GPS immunotherapy data, while 8-K material events flag trial pauses, licensing milestones, or new ATM financings. Tracking those disclosures—and the executive stock transactions Form 4 that sometimes precede them—takes time most investors don’t have.
That’s why Stock Titan brings every SELLAS Life Sciences quarterly earnings report 10-Q filing, insider trading Form 4 transactions and proxy statement executive compensation section into one AI-powered view. Our engine converts technical language into plain English, so understanding SELLAS Life Sciences SEC documents with AI becomes as direct as reading a headline. Need the latest SELLAS Life Sciences Form 4 insider transactions real-time? You’ll see alerts within minutes of EDGAR posting. Curious how cash burn compares Q-over-Q? The platform highlights the numbers for you, then links straight to the audited footnote.
- Instant summaries that make the SELLAS Life Sciences annual report 10-K simplified—focus on drug-development timelines, dilution risks and collaboration revenue.
- Auto-tagged sections so you can jump to “research & development expense” or “ASXL1 biomarker data” without scrolling 200 pages.
- Side-by-side analysis of every SELLAS Life Sciences earnings report filing analysis for trend spotting.
- One-click access to SELLAS Life Sciences 8-K material events explained, from FDA designations to financing agreements.
Whether you want SELLAS Life Sciences insider trading Form 4 transactions before the next 8-K, or just a clear view of how GPS milestones impact valuation, our real-time feed and concise AI commentary turn dense disclosures into actionable insight—no biotech PhD required.
The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.
- Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
- Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
- Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
- Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
- Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
- Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.
No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.